CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOAD

Trial Profile

CLINICAL TRIAL WITH TENOFOVIR VERSUS LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN LAMIVUDINE-RESISTANT CHRONIC HEPATITIS-B PATIENTS WITH UNDETECTABLE VIRAL LOAD

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms TENOSIMP-B
  • Most Recent Events

    • 28 May 2016 Status changed from recruiting to completed.
    • 13 Apr 2014 Primary endpoint 'Sustained-virological-response-rate' has been met according to abstract published at the 49th Annual Meeting of the European Association for the Study of the Liver.
    • 13 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top